Sex: F
Vaccine: COVID19
Symptoms: Basedow's disease, Blood thyroid stimulating hormone, Heart rate, Investigation, Thyroxine
Clinical narrative: GRAVES' DISEASE; This is a literature report for the following literature source(s): "TWO CASES OF GRAVES' DISEASE IN ADOLESCENTS FOLLOWING COVID-19 VACCINATIONS", Thyroid.  A 15-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: BASEDOW'S DISEASE (medically significant), outcome "recovering", described as "GRAVES' DISEASE". The patient underwent the following laboratory tests and procedures: Blood thyroid stimulating hormone: less than 0.005, notes: Unit: uI/mL suppressed; less than 0.005, notes: Unit: uI/mL Repeat bloodwork a month later; normal thyroid function; Heart rate: 130, notes: unit: bpm tachycardia while resting; greater than 200, notes: during exercise; TSI: unknown result; decreasing, notes: subsequent bloodwork; undetectable, notes: 3 months after initiating treatment; Thyroxine: 12.8, notes: Unit: mcg/dL Repeat bloodwork a month later; improvement, notes: subsequent bloodwork; normal thyroid function, notes: 3 months after initiating treatment; Thyroxine free: 2.57 ng/dL; improvement, notes: subsequent bloodwork; normal thyroid function, notes: 3 months after initiating treatment; Tri-iodothyronine: 223 ng/dL, notes: Repeat bloodwork a month later; improvement, notes: subsequent bloodwork; normal thyroid function, notes: 3 months after initiating treatment. Therapeutic measures were taken as a result of basedow's disease.  Clinical course: Presented to her pediatrician for evaluation of distorted vision upon standing. She received her first and second Pfizer-BioNTech COVID-19 vaccines two months and one month before presentation, respectively.She was started on Methimazole; subsequent bloodwork showed improvement in her thyroid function tests, decreasing TSI, and improvement in symptoms. The patient was taken off Methimazole 3 months after initiating treatment and her most recent bloodwork showed undetectable TSI with normal thyroid function.case series is the first to demonstrate Graves' disease after COVID-19 vaccination in the pediatric population. Given this possibility, pediatricians need to be watchful for symptoms of Graves' disease post-vaccination to prevent treatment delays.; Sender's Comments: As there is limited information in the case provided, the causal association between the event Basedow's disease and the suspect product BNT162B2 cannot be excluded. The case will be reassessed once new information is available.  The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202201277498 Same article/drug/event different patient.;